VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 25, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (“ALDA” or the “Company”) has recently been through a vigorous review of its annual and interim financial disclosure and related management discussion and analysis as part of the British Columbia Securities Commission’s (“BCSC”) ongoing Continuous Disclosure Review Program. This program is intended to ensure that reporting issuers comply with applicable securities regulations and is meant to improve the quality of disclosure to shareholders and other market participants. The review focused on the Company’s financial disclosure for the year ended June 30, 2007 and the subsequent quarterly periods ended September 30, 2007 and December 31, 2007.
